title: Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
abstract: The effects of various factors, including the cytochrome P450 (CYP) 2D6 genotype and the coadministration of flunitrazepam, on the steady-state plasma concentrations (Css) of bromperidol and its reduced metabolite were studied in 62 schizophrenic inpatients receiving bromperidol 12 mg/day. By use of allele-specific PCR analysis, the wild type allele (CYP2D6*1A) and four mutated alleles causing either absent (CYP2D6*3, CYP2D6*4 and CYP2D6*5) or decreased (CYP2D6*10) CYP2D6 activity were identified. The means (ranges) of the Css of bromperidol and reduced bromperidol corrected to the median body weight were 7.2 (1.3-17.4) and 2.2 (0.4-8.9) ng/ml, respectively. Neither the Css of bromperidol nor that of reduced bromperidol significantly differed among the patients with no (n = 28), one (n = 30) and two mutated alleles (n = 4). The patients coadministered with flunitrazepam (n = 52) had significantly (P < 0.05) higher Css of bromperidol, but not reduced bromperidol, than those not (n = 10). Age, sex and smoking had no significant effects on the Css of these compounds. The present study thus suggests that the polymorphic CYP2D6 is not involved in the metabolism of bromperidol and reduced bromperidol to a major extent. The coadministration of flunitrazepam inhibits the metabolism of bromperidol, but age, sex and smoking do not affect it.
authors.affiliation: Department of Neuropsychiatry, Hirosaki University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Otani
authors.forename: K
authors.initials: K
authors.lastname: Mihara
authors.forename: N
authors.initials: N
authors.lastname: Yasui
authors.forename: T
authors.initials: T
authors.lastname: Kondo
authors.forename: N
authors.initials: N
authors.lastname: Tokinaga
authors.forename: H
authors.initials: H
authors.lastname: Furukori
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
authors.forename: Y
authors.initials: Y
authors.lastname: Inoue
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000097:blood* / Q000627:therapeutic use; D001711:Biotransformation; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D005445:Flunitrazepam / Q000494:pharmacology*; D005838:Genotype; D006207:Half-Life; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D012727:Sex Characteristics; D012907:Smoking / Q000378:metabolism
chemical_list: D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D005445:Flunitrazepam; D019389:Cytochrome P-450 CYP2D6; D006220:Haloperidol; C006820:bromperidol